Difelikefalin
Sponsors
Cara Therapeutics Inc., Cara Therapeutics, Inc., Vifor Fresenius Medical Care Renal Pharma
Conditions
Chronic Kidney DiseasesModerate-to-Severe pruritus in adult subjects with notalgia parestheticaPruritusUremic Pruritus
Phase 2
A 2-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate-to-Severe Pruritus in Adult Subjects with Notalgia Paresthetica
CompletedCTIS2023-503957-36-00
Start: 2023-12-04End: 2024-06-12Target: 193Updated: 2024-04-29
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
RecruitingNCT06593392
Start: 2026-08-04End: 2029-08-15Target: 18Updated: 2026-09-01